



THE BRITISH JOURNAL OF PSYCHIATRY

June 1995

Vol. 166

Editorials

Services for younger sufferers of Alzheimer's disease. *D. D. R. Williams*

Dreadlocks and mental disease. An old argument and an early epidemiological study (1843). *H. Förstl and H. Elliger*

A Medical Research Council initiative in mental handicap. *W. I. Fraser*

Review Article

Assessment and treatment approaches for survivors of torture. *R. J. Mclvor and S. W. Turner*

Papers

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. *J. Peuskens, on behalf of the Risperidone Study Group*

Peer review of "Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol". *A. L. Johnson and D. A. W. Johnson*

Antecedents of schizophrenia and affective illness. Obstetric complications. *A. Sacker, D. J. Done, T. J. Crow and J. Golding*

Normal asymmetry of the planum temporale in patients with schizophrenia. Three-dimensional

cortical morphometry with MRI. *J. J. Kulynych, K. Vldar, B. D. Fantie, D. W. Jones and D. R. Weinberger* 742

Increased intracerebral cerebrospinal fluid spaces predict unemployment and negative symptoms in psychotic illness. A prospective study. *J. van Os, T. A. Fahy, P. Jones, I. Harvey, S. Lewis, M. Williams, B. Toone and R. Murray* 750

Socio-economic mobility among patients with schizophrenia or major affective disorder. A 17-year retrospective follow-up. *S. Aro, H. Aro and I. Keskimäki* 759

Neuroleptic associated tardive dyskinesias in young people with psychoses. *E. Pourcher, P. Baruch, R. H. Bouchard, M.-J. Filteau and D. Bergeron* 768

The omnipotence of voices. II: The Beliefs About Voices Questionnaire (BAVQ). *P. Chadwick and M. Birchwood* 773

Dependency and community care in presenile Alzheimer's disease. *A. J. Newens, D. P. Forster and D. W. K. Kay* 777

Mortality among patients with psychiatric illness. A ten-year case register study in an area with a community-based system of care. *F. Amadeo, G. Bisoffi, P. Bonizzato, R. Micciolo and M. Tansella* 783

734 Autonomic failure, depression and anxiety in

continued p. ii

Published by The Royal College of Psychiatrists

ISSN 0007-1250

Lundbeck

IF YOU
COULD
TRUST
HIM TO
TAKE
HIS
TABLETS

HE PROBABLY
WOULDN'T
NEED THEM

Further information is available
from: Lundbeck Limited,
Sunningdale House,
Caldecotte Lake Business Park,
Caldecotte, Milton Keynes, MK7 8LF.

DEPOT
DEPIXOL
cis(Z)-flupenthixol decanoate

the way home

The British Journal of Psychiatry

June 1995

Volume 166

No. 6

Editor Greg Wilkinson *Liverpool*

Senior Associate Editor

Alan Kerr *Newcastle upon Tyne*

Associate Editors

Sidney Crown *London*

Julian Leff *London*

Sir Martin Roth *Cambridge*

Peter Tyrer *London*

Editorial Advisers

Herschel Prins *Leicester*

Sir John Wood *Sheffield*

Assistant Editors

Mohammed Abou-Saleh *Al-Ain*

Louis Appleby *Manchester*

German Berrios *Cambridge*

Alistair Burns *Manchester*

Patricia Casey *Dublin*

John Cookson *London*

David Cottrell *Leeds*

Nigel Eastman *London*

Tom Fahy *London*

Anne Farmer *Cardiff*

Nicol Ferrier *Newcastle upon Tyne*

William Fraser *Cardiff*

Richard Harrington *Manchester*

Sheila Hollins *London*

Jeremy Holmes *Barnstaple*

Alexander Kellam *Cardiff*

Peter Kennedy *York*

Alan Lee *Nottingham*

Robin McCreadie *Dumfries*

Ian McKeith *Newcastle upon Tyne*

Roy McClelland *Belfast*

Stuart Montgomery *London*

David Owens *Leeds*

Ian Pullen *Edinburgh*

Rosalind Ramsay *London*

Henry Rollin *London*

Jan Scott *Newcastle upon Tyne*

Andrew Sims *Leeds*

George Stein *London*

David Tait *Perth*

Corresponding Editors

Sidney Bloch *Australia*

Patrice Boyer *France*

J.M. Caldas de Almeida *Portugal*

Andrew Cheng *Taiwan*

Andrei Cristian *Romania*

E. L. Edelstein *Israel*

Václav Filip *Czech Republic*

Heinz Katschnig *Austria*

Kenneth Kendler *USA*

Toshi Kitamura *Japan*

Arthur Kleinman *USA*

F. Lieh Mak *Hong Kong*

Jair Mari *Brazil*

Harold Merskey *Canada*

Paul Mullen *Australia*

Ahmed Okasha *Egypt*

Volodymer Poltavetz *Ukraine*

Michele Tansella *Italy*

Toma Tomov *Bulgaria*

John Tsiantis *Greece*

J. L. Vázquez-Barquero *Spain*

Richard Warner *USA*

Statistical Adviser

Pak Sham *London*

Staff

Publications Manager

Dave Jago

Scientific Editor

Lesley Bennun

Deputy Scientific Editor

Aliki Buhayer

Assistant Scientific Editor

Samantha Jones

Editorial Assistants

Judy Ashworth

Julia Burnside

Marketing Assistant

Dominic Bentham

Past Editors

Eliot Slater 1961–72 Edward H. Hare 1973–77 John L. Crammer 1978–83 Hugh L. Freeman 1984–93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963

Published by the Royal College of Psychiatrists

Contents continued from front cover

Parkinson's disease. <i>G. E. Berrios, C. Campbell and B. E. Politynska</i>	789
Chronic fatigue syndrome in the community. Prevalence and associations. <i>S. M. Lawrie and A. J. Pelosi</i>	793
A clinical study of chronic fatigue syndrome. <i>M. F. Shanks and D. O. Ho-Yen</i>	798
The Belmarsh Scheme. A prospective study of the transfer of mentally disordered remand prisoners from prison to psychiatric units. <i>S. Banerjee, K. O'Neill-Byrne, T. Exworthy and J. Parrott</i>	802
The social disablement of men in hostels for homeless people. I. Reliability and prevalence. <i>W. A. Hamid, T. Wykes and S. Stansfeld</i>	806

The social disablement of men in hostels for homeless people. II. A comparison with patients from long-stay wards. <i>W. A. Hamid, T. Wykes and S. Stansfeld</i>	809
The genetic epidemiology of self-esteem. <i>M.-A. Roy, M. C. Neale and K. S. Kendler</i>	813

Columns

Correspondence	821
A hundred years ago	828
Book reviews	829
American Journal of Psychiatry (<i>contents</i>)	836

Next month in the BJP

An approach (and its antecedents) to a Darwinian theory of the origins of psychosis. *T. J. Crow*

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. All communications, including manuscripts for publication, should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG.

Full instructions to authors are given at the beginning of the January and July issues.

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1995 (12 issues post free) are as follows:

Europe (& UK): institutions £148, individuals £130
US: institutions \$295, individuals \$210
Elsewhere: institutions £175, individuals £138
Full airmail is £36/US\$64 extra.
Single copies of the Journal are £14, \$25 (post free).

Payment should be made out to the British Journal of Psychiatry.

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

© 1995 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

Back issues

Back issues published before 1995 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$295. Second class postage paid at Rahway, NJ. Postmaster send address corrections to the *British Journal of Psychiatry*, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

©™ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences – Permanence of Paper for Printed Library Materials. ANSI Z39.48–1984.

Typeset by Dobbie Typesetting Ltd, Tavistock, and Henry Ling Ltd.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

THE TAVISTOCK CLINIC

Psychodynamics for Psychiatrists

A Brief Introductory Course

This one week course will include topics relevant to the MRCPsych examination and will give a theoretical basis in line with the recent college requirements for psychotherapy training for psychiatrists.

It will be of interest to trainees as well as psychiatrists wishing to gain further knowledge.

Speakers will include:

Dr Robin Anderson	Professor Peter Hobson
Dr Sebastian Kraemer	Dr Anton Obholzer
Dr John Steiner	Dr David Taylor
Dr Nick Temple	Dr Judith Trowell

Monday 17 to Friday 21 July 1995

Fee: £210.00

Enquiries to: Dr Rob Hale FRCPsych, The Portman Clinic, 8 Fitzjohn's Avenue, London NW3 5NA
Tel: 0171 794 8262

Application forms available from:
The Conference Unit,
120 Belsize Lane, London, NW3 5BA,
or telephone 0171-435 8721
Please quote ref C63

P

THE TAVISTOCK & PORTMAN NHS TRUST

THE TAVISTOCK CLINIC

75th Anniversary Conference

Mind in the Balance: Issues in Mental Health

to be held at Regents College, London
18-19 September 1995

This two day conference will be of interest to all those involved in the field of mental health and is the Clinic's opportunity to celebrate with you not only the past 75 years of our history but also current work which will take us forward to meet the demands of a rapidly changing society.

Further information and application forms available from:
The Conference Unit,
THE TAVISTOCK CLINIC,
120 Belsize Lane, London, NW3 5BA,
or telephone 0171-435 8721
Please quote ref C63

P



NB

MEDICAL
EDUCATION

LONDON

MRCPsych PART I

Intensive exam-orientated weekend courses

- covering: Theory
Technique & tactics
Over 600 past MCQs
Practice MCQ exams
- dates: 12, 13 & 19, 20 August 1995

The Secretary
NB Medical Education
18/20 Rosendale Road
West Dulwich
London SE21 8DP


- Full details: 0181 766 0125
- HM 67 (27) approval for study leave

—INTRODUCING—

THE WORLD'S FIRST

S · N · R · I

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR



Space photographs provided courtesy of National Aeronautics and Space Administration (NASA)

The result of original Wyeth research and development, Efexor (venlafaxine) is the first of a new class of antidepressants, the SNRIs.

Efexor is a major step forward in selective reuptake inhibition and increases the availability of both of the key neurotransmitters involved in depression.¹ This is in line with current thinking on the pathophysiology of depression, which stresses the importance of interactions between serotonin and noradrenaline.²

Extensive clinical trials of Efexor in over 2,500 depressed patients have confirmed the success of this approach. Efexor has been shown to be at least as effective and better tolerated than standard tricyclic and related antidepressants such as dothiepin, imipramine and trazodone.¹

Efexor has also been shown to compare favourably with the SSRI fluoxetine in inpatient¹ and outpatient studies.¹ Furthermore, Efexor demonstrates a significant dose response curve which allows flexibility of treatment in a wide range of patients.¹

For many depressed patients, the world's first SNRI could make a world of difference.

EFEXOR[®] ▼
VENLAFAXINE

A NEW CLASS OF ANTIDEPRESSANT

PRESCRIBING INFORMATION: PRESENTATION: Tablets containing 37.5mg or 75mg venlafaxine (as hydrochloride). USE: Treatment of depressive illness. DOSAGE: Usually 75mg/day (37.5mg bd) with food, increasing to 150mg/day (75mg bd) if necessary. In more severely depressed patients, 150mg/day (75mg bd) increasing every 2 or 3 days in up to 75mg/day increments to maximum 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly: use normal adult dose. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS: Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS: Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their

ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their Doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS: MAOIs: do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting a MAOI. SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety,

impotence, abnormality of accommodation, vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol. BASIC NHS PRICE: 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets: £23.97. 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets: £39.97. LEGAL CATEGORY: POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire SL6 0PH. REFERENCES: 1. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9: 139-142. 2. Kalus O, Asnis GH, van Praag HM, *Psychiatric Annals* 1989; 19: 348-353. 3. Data on file, Medical Affairs Department, Wyeth-Ayerst International Inc. Date of Preparation: December 1994. Code Z770380/1294. *EFEXOR is a registered trademark.